keyword
MENU ▼
Read by QxMD icon Read
search

abatacept rheumatoid arthritis

keyword
https://www.readbyqxmd.com/read/28079510/a-comparison-of-discontinuation-rates-of-tofacitinib-and-biologic-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-a-systematic-review-and-bayesian-network-meta-analysis
#1
Sun-Kyeong Park, Min-Young Lee, Eun-Jin Jang, Hye-Lin Kim, Dong-Mun Ha, Eui-Kyung Lee
OBJECTIVES: The purpose of this study was to compare the discontinuation rates of tofacitinib and biologics (tumour necrosis factor inhibitors (TNFi), abatacept, rituximab, and tocilizumab) in rheumatoid arthritis (RA) patients considering inadequate responses (IRs) to previous treatment(s). METHODS: Randomised controlled trials of tofacitinib and biologics - reporting at least one total discontinuation, discontinuation due to lack of efficacy (LOE), and discontinuation due to adverse events (AEs) - were identified through systematic review...
January 5, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28058538/factors-influencing-the-choice-of-first-and-second-line-biologic-therapy-for-the-treatment-of-rheumatoid-arthritis-real-life-data-from-the-italian-lorhen-registry
#2
Sara Monti, Catherine Klersy, Roberto Gorla, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Raffaele Pellerito, Enrico Fusaro, Giuseppe Paolazzi, Pier Andrea Rocchetta, Ennio Giulio Favalli, Antonio Marchesoni, Roberto Caporali
According to international recommendations, the selection of the biologic disease modifying anti-rheumatic drug (bDMARD) for rheumatoid arthritis (RA) is mainly left to the clinician's preference. We analyzed the real-life factors influencing the first-line choice or the switching strategy, focusing on the prescription of abatacept (ABA) or tocilizumab (TCZ) compared to TNFα inhibitors (TNFi). Patients enrolled in the Lombardy Rheumatology Network (LORHEN) Registry after January 1, 2010, when all considered bDMARD agents were available, were included...
January 5, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28053274/safety-of-surgery-in-patients-with-rheumatoid-arthritis-treated-by-abatacept-data-from-the-french-orencia-in-rheumatoid-arthritis-registry
#3
Augustin Latourte, Jacques-Eric Gottenberg, Cécile Luxembourger, Isabelle Pane, Pascal Claudepierre, Pascal Richette, Pierre Lafforgue, Bernard Combe, Alain Cantagrel, Jean Sibilia, René-Marc Flipo, Philippe Gaudin, Olivier Vittecoq, Thierry Schaeverbeke, Maxime Dougados, Jeremie Sellam, Philippe Ravaud, Xavier Mariette, Raphaèle Seror
OBJECTIVE: To investigate the frequency and risk factors of postoperative complications in RA patients treated with abatacept (ABA). METHODS: The Orencia RA registry recruited 1012 patients receiving ABA for RA in routine care. Data from patients treated with ABA who underwent surgery were reviewed to describe the frequency of postoperative complications. Characteristics of patients and surgeries with and without complications were compared to identify factors associated with complications...
January 3, 2017: Rheumatology
https://www.readbyqxmd.com/read/28043761/the-effect-of-body-mass-index-on-clinical-response-to-abatacept-as-a-first-line-biologic-for-rheumatoid-arthritis-6-month-results-from-the-2-year-observational-prospective-action-study
#4
Xavier Mariette, Rieke Alten, Hubert G Nüßlein, Mauro Galeazzi, Hanns-Martin Lorenz, Alain Cantagrel, Melanie Chartier, Coralie Poncet, Christiane Rauch, Manuela Le Bars
OBJECTIVE: To assess the impact of baseline body mass index (BMI) on the efficacy and retention of intravenous abatacept at 6 months in biologic-naïve patients with rheumatoid arthritis (RA). METHODS: This was a 6-month analysis of a 2-year, non-interventional, international, prospective study. Baseline characteristics, clinical response and retention rates were compared by BMI subgroup: underweight/normal, overweight and obese (<25, 25 to <30 and ≥30kg/m(2), respectively)...
December 30, 2016: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28034349/biological-agents-in-rheumatoid-arthritis-a-cross-link-between-immune-tolerance-and-immune-surveillance
#5
Rossella Talotta, Fabiola Atzeni, Alberto Batticciotto, Maurizio Benucci, Sara Bongiovanni, Piercarlo Sarzi-Puttini
The biological drugs have all been successfully used to treat rheumatoid arthritis (RA) and have led to fair rates of clinical remission; however, the possible occurrence of adverse events such as infectious diseases or cancers means that the patients undergoing treatment need to be closely monitored. Anti-TNF agents, first appeared in the pharmacological algorithm of RA in the early 2000s, seem to lead to a higher risk of reactivated tubercular infection than the biological agents with different mechanism of action (abatacept or rituximab)...
December 30, 2016: Current Rheumatology Reviews
https://www.readbyqxmd.com/read/28013201/risk-of-serious-adverse-effects-of-biological-and-targeted-drugs-in-patients-with-rheumatoid-arthritis-a-systematic-review-meta-analysis
#6
Simon Tarp, Daniel Eric Furst, Maarten Boers, George Luta, Henning Bliddal, Ulrik Tarp, Karsten Heller Asmussen, Birgitte Brock, Anna Dossing, Tanja Schjødt Jørgensen, Steffen Thirstrup, Robin Christensen
OBJECTIVES: To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA. METHODS: Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts-DMARDs for RA. Network meta-analyses using mixed-effects Poisson regression models were conducted to calculate rate ratios for serious adverse events (SAEs) and deaths between each of the 10 drugs and control (i...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28010149/outcomes-of-tumor-necrosis-factor-inhibitor-cycling-versus-switching-to-a-disease-modifying-anti-rheumatic-drug-with-a-new-mechanism-of-action-among-patients-with-rheumatoid-arthritis
#7
Benjamin Chastek, Laura K Becker, Chieh-I Chen, Puneet Mahajan, Jeffrey R Curtis
OBJECTIVES: To examine treatment patterns, treatment effectiveness, and treatment costs for 1 year after patients with rheumatoid arthritis switched from a tumor necrosis factor inhibitor (TNFi) (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab), either cycling to another TNFi ("TNFi cyclers") or switching to a new mechanism of action (abatacept, tocilizumab, or tofacitinib) ("new MOA switchers"). METHODS: This retrospective cohort study used administrative claims data for a national insurer...
January 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/27974925/new-pharmacological-strategies-in-rheumatic-diseases
#8
REVIEW
Schiotis Re, Buzoianu Ad, Mureșanu Df, Suciu S
Targeting the pathogenic pathway of chronic inflammation represents an unmet challenge for controlling disease activity, preventing functional disability, and maintaining an adequate quality of life in patients with rheumatic diseases. Abatacept, a novel molecule that inhibits co-stimulation signal, induces an inhibitory effect on the T-cells. This will further interfere with the activity of several cell lines, leading to the normalization of the immune response. In the latest years, abatacept has been extensively investigated in studies of rheumatoid arthritis for which it was recently approved as a second line biologic treatment in Romania...
July 2016: Journal of Medicine and Life
https://www.readbyqxmd.com/read/27971460/a-cost-effectiveness-analysis-of-abatacept-tocilizumab-and-tnf-inhibitor-compared-with-rituximab-as-a-second-line-therapy-for-treatment-of-rheumatoid-arthritis
#9
S Huoponen, K J Aaltonen, J T Joensuu, J Rutanen, H Relas, K Taimen, K Puolakka, T Sokka, D Nordström, M Blom
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971459/economic-evaluation-of-tocilizumab-vs-abatacept-in-methotrexate-experienced-patients-with-rheumatoid-arthritis-in-italy
#10
S Villa, R Ravasio, F Rossetti, L Bianchino
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27966068/body-mass-does-not-impact-the-clinical-response-to-intravenous-abatacept-in-patients-with-rheumatoid-arthritis-analysis-from-the-pan-european-registry-collaboration-for-abatacept-panaba
#11
Florenzo Iannone, Delphine S Courvoisier, Jacques Eric Gottenberg, Maria Victoria Hernandez, Elisabeth Lie, Helena Canhão, Karel Pavelka, Merete Lund Hetland, Carl Turesson, Xavier Mariette, Denis Choquette, Axel Finckh
Some evidences suggest that obesity impairs the effectiveness of TNF inhibitors. We examined the impact of body mass index (BMI) on the clinical effectiveness of abatacept in rheumatoid arthritis (RA) patients. This is a pooled analysis of 10 prospective cohorts of RA patients. All patients with available BMI were included in this study. The primary endpoint was drug retention of abatacept in the different BMI categories. Multivariable Cox regression was used to estimate hazard ratios (HRs) for drug discontinuation...
December 14, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27919316/corrigendum-adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-not-previously-treated-with-disease-modifying-antirheumatic-drugs-and-after-the-failure-of-conventional-disease-modifying
#12
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young, Allan Wailoo
No abstract text is available yet for this article.
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27914689/efficacy-of-biologic-therapy-across-individual-juvenile-idiopathic-arthritis-subtypes-a-systematic-review
#13
REVIEW
Rebecca Davies, Danielle Gaynor, Kimme L Hyrich, Clare E Pain
OBJECTIVE: To determine the efficacy of differing biologic therapies amongst individual juvenile idiopathic arthritis (JIA) subtypes rather than JIA overall. METHODS: A systematic literature review was conducted between January 1975 and November 2014. Studies included were randomised controlled trials, controlled trials, non-randomised prospective studies or case-control studies. Subjects were required to have a diagnosis of JIA and were ≤20 years of age at study entry...
November 1, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27914602/severe-infection-in-patients-with-rheumatoid-arthritis-taking-anakinra-rituximab-or-abatacept-a-systematic-review-of-observational-studies
#14
Vanderlea Poeys Cabral, Carlos Augusto Ferreira de Andrade, Sonia Regina Lambert Passos, Maria de Fátima Moreira Martins, Yara Hahr Marques Hökerberg
A question is raised about an increased risk of severe infection from the use of biological drugs in patients with rheumatoid arthritis. This systematic review of observational studies aimed at assessing the risk of severe infection associated with the use of anakinra, rituximab, and abatacept in patients with rheumatoid arthritis. The following databases were searched: PubMed, Science Direct, Scopus, Web of Knowledge, Scirus, Cochrane, Exerpta Medica Database, Scielo, and Lilacs up to July 2010. Severe infections were defined as those life-threatening ones in need of the use of parenteral antibiotics or of hospitalization...
November 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/27909436/evaluation-of-anti-inflammatory-effects-of-steroids-and-arthritis-related-biotherapies-in-an-in-vitro-coculture-model-with-immune-cells-and-synoviocytes
#15
Mélissa Noack, Ndiémé Ndongo-Thiam, Pierre Miossec
BACKGROUND: During rheumatoid arthritis (RA), steroids and biotherapies are used alone and combined. Efficacy has been established in clinical trials but their differential effects at the cellular level are less documented. The aim was to study these cellular effects using an in vitro model with synoviocytes interacting with peripheral blood mononuclear cells (PBMC) to reproduce the interactions in the RA synovium. METHODS: Activated-PBMC were cocultured with RA synoviocytes during 48 h...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27906048/comparative-effectiveness-of-abatacept-versus-tocilizumab-in-rheumatoid-arthritis-patients-with-prior-tnfi-exposure-in-the-us-corrona-registry
#16
Leslie R Harrold, George W Reed, Daniel H Solomon, Jeffrey R Curtis, Mei Liu, Jeffrey D Greenberg, Joel M Kremer
BACKGROUND: We compared the effectiveness of abatacept (ABA) vs tocilizumab (TCA) in tumor necrosis factor inhibitor (TNFi) experienced patients. METHODS: We identified rheumatoid arthritis (RA) patients from a large observational US cohort (1 January 2010-31 May 2014) who had discontinued at least one TNFi and initiated ABA or TCZ in moderate or high disease activity based on the Clinical Disease Activity Index (CDAI) and had no prior exposure to the comparator drug...
December 1, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27889300/tofacitinib-versus-biologic-treatments-in-patients-with-active-rheumatoid-arthritis-who-have-had-an-inadequate-response-to-tumor-necrosis-factor-inhibitors-results-from-a-network-meta-analysis
#17
Maria-Cecilia Vieira, Samuel H Zwillich, Jeroen P Jansen, Brielan Smiechowski, Dean Spurden, Gene V Wallenstein
PURPOSE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis compared the efficacy and safety of tofacitinib with biologic disease-modifying antirheumatic drugs in patients with RA and a prior inadequate response (IR) to tumor necrosis factor inhibitors (TNFi). METHODS: A systematic literature review identified 5 randomized placebo-controlled trials that evaluated tofacitinib or biologic disease-modifying antirheumatic drugs (bDMARDs) against placebo in patient populations with RA with a prior IR to TNFi...
December 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27882833/evaluation-of-real-world-experience-with-tofacitinib-compared-with-adalimumab-etanercept-and-abatacept-in-ra-patients-with-1-previous-biologic-dmard-data-from-a-u-s-administrative-claims-database
#18
James Harnett, Robert Gerber, David Gruben, Andrew S Koenig, Connie Chen
BACKGROUND: Real-world data comparing tofacitinib with biologic disease-modifying antirheumatic drugs (bDMARDs) are limited. OBJECTIVE: To compare characteristics, treatment patterns, and costs of patients with rheumatoid arthritis (RA) receiving tofacitinib versus the most common bDMARDs (adalimumab [ADA], etanercept [ETN], and abatacept [ABA]) following a single bDMARD in a U.S. administrative claims database. METHODS: This study was a retrospective cohort analysis of patients aged ≥ 18 years with an RA diagnosis (ICD-9-CM codes 714...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27855242/biologic-or-tofacitinib-monotherapy-for-rheumatoid-arthritis-in-people-with-traditional-disease-modifying-anti-rheumatic-drug-dmard-failure-a-cochrane-systematic-review-and-network-meta-analysis-nma
#19
REVIEW
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell, George A Wells
BACKGROUND: We performed a systematic review, a standard meta-analysis and network meta-analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD-experienced). OBJECTIVES: To assess the benefits and harms of biologic monotherapy (includes anti-tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD-experienced...
17, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27846756/simplified-disease-activity-index-remission-at-month-6-is-an-independent-predictor-of-functional-and-structural-remissions-at-month-12-during-abatacept-treatment-in-patients-with-rheumatoid-arthritis-a-multi-center-prospective-cohort-study-in-japan
#20
Hayato Yamazaki, Fumio Hirano, Tsutomu Takeuchi, Koichi Amano, Jun Kikuchi, Mari Kihara, Waka Yokoyama, Takahiko Sugihara, Kenji Nagasaka, Hiroyuki Hagiyama, Yoshinori Nonomura, Ryoko Sakai, Michi Tanaka, Ryuji Koike, Toshihiro Nanki, Hitoshi Kohsaka, Nobuyuki Miyasaka, Masayoshi Harigai
OBJECTIVE: To evaluate association of clinical remission at month 6 with functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis (RA). METHODS: This 12-month prospective, multicenter cohort study enrolled 168 patients with RA who started abatacept. Outcomes were assessed using composite measures, quality of life indices, and the van der Heijde-modified total Sharp score (mTSS). The logistic regression analysis was applied to identify factors associated with outcomes and their odds ratios (OR) with 95% confidence interval (95% CI)...
December 15, 2016: Modern Rheumatology
keyword
keyword
94163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"